Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Bakelite Files Application for Gene Chip for Cancer Diagnosis
July 11, 2013
- Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
- PTH Preparations, New Drugs Grow in Intense Anti-Osteoporosis Drug Competition
July 10, 2013
- Kyowa Kirin Aims to Lead the Domestic Parkinson’s Disease Market in 5 Years on the Strength of Nouriast and 3 Other Products
July 10, 2013
- Will the ARB Market Regain Steam in FY2013? Leading ARB Drug Marketers Forecast Double-digit Growth in FY2013
July 10, 2013
- High Price, Concerns About Safety Could Pose Hurdle to Success of Pfizer Japan’s Xeljanz
July 10, 2013
- Kyowa Kirin Steps into Diabetes Market with 7th DPP-4 Inhibitor Onglyza
July 9, 2013
- CMIC Subsidiary SSI to Set Up Committee to Investigate Suspected Clinical Data Manipulation
July 9, 2013
- Ethical Drug Sales Up 3.3% in May: Crecon Report
July 9, 2013
- Kyorin to Merge 2 Domestic Development Sites in Tochigi Prefecture
July 8, 2013
- Daiichi Sankyo to Promote Osteoporosis Treatment Pralia with Focus on Appropriate Use
July 5, 2013
- Over 60% of Cancer Patients Aware of Generic Cancer Treatment Options: Sawai Survey
July 5, 2013
- Fujifilm to Begin PIII Study of Personalized Peptide Cancer Vaccine
July 5, 2013
- AY Pharmaceuticals Starts Operations, Yoshindo Bolsters Sales, Marketing System
July 5, 2013
- Hanshin DP Holdings, Medical System Network Establish New JV to Support Efficient Distribution
July 5, 2013
- Importance of Personal Relationships, Low Use of Generics Contribute to Persistence of SOV Model in Japan, but Change is Likely
July 5, 2013
- MTPC Begins Construction of New Head Office Building, Expects Completion in January 2015
July 4, 2013
- Generic Industry Needs to Produce 30 Billion More Tablets to Meet 60% Generic Share Goal: Sawai President
July 4, 2013
- Out-Licensed OAB Treatment Imidafenacin Launched in South Korea: Kyorin Holdings
July 4, 2013
- Low-Dose Lunabell Approved
July 4, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…